Type 1 diabetes treatment could end need for insulin shots

Cell and Gene Therapy Catapult and Aberdeen University are working on lab-grown treatment that could help hundreds of thousands of people

Insulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.

The pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa. It will manufacture lab-grown islets, the organoids responsible for insulin production, by reprogramming donated pancreatic tissue.